Tenaya Therapeutics (TNYA) Preferred Stock Liabilities (2020 - 2021)
Tenaya Therapeutics (TNYA) recorded quarterly Preferred Stock Liabilities of $240.7 million in Q2 2021, little changed quarter-over-quarter from $240.7 million in Q1 2021, and up 132.12% on a YoY basis from $103.7 million in Q2 2020.
Tenaya Therapeutics (TNYA) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Tenaya Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $240.7 million for Q2 2021.
- In Q2 2021, Preferred Stock Liabilities rose 132.12% year-over-year to $240.7 million; the TTM figure through Jun 2021 stood at $240.7 million (up 132.12% YoY), while the FY2020 annual figure was $220.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $240.7 million for Q2 2021 at Tenaya Therapeutics, roughly flat from $240.7 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $240.7 million in Q1 2021 to a low of $103.7 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Tenaya Therapeutics | 154.33 Mn | 154.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 240.74 Mn |
| Mar 31, 2021 | 240.74 Mn |
| Dec 31, 2020 | 220.75 Mn |
| Sep 30, 2020 | 135.04 Mn |
| Jun 30, 2020 | 103.71 Mn |